Simcere Pharmaceutical Group Ltd
02096
Company Profile
Business description
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
Contact
No. 699-18, Xuanwu Road
Xuanwu District
Jiangsu Province
Nanjing210042
CHNT: +86 2585566666
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
7,038
Stocks News & Analysis
stocks
Cheap ASX share may have more room to run
Shares are cheap despite rebounding share price, yet risks remain.
stocks
ASX listed media giant drives strong earnings growth
Digital growth drives earnings beat for media share.
stocks
ASX real estate platform outperforms yet questions remain
Valuation remains a key concern despite strong August reporting.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,424.30 | 13.10 | -0.14% |
| CAC 40 | 8,714.93 | 15.22 | 0.17% |
| DAX 40 | 26,319.45 | 179.32 | 0.69% |
| Dow JONES (US) | 54,036.93 | 151.83 | 0.28% |
| FTSE 100 | 10,901.09 | 33.20 | 0.31% |
| HKSE | 25,880.11 | 212.08 | 0.83% |
| NASDAQ | 26,690.62 | 342.26 | 1.30% |
| Nikkei 225 | 66,879.12 | 1,272.41 | 1.94% |
| NZX 50 Index | 13,888.24 | 64.11 | 0.46% |
| S&P 500 | 7,757.64 | 47.68 | 0.62% |
| S&P/ASX 200 | 9,233.40 | 16.20 | -0.18% |
| SSE Composite Index | 3,952.54 | 12.50 | 0.32% |